Ideaya Biosciences

GSK walks away from remaining IDEAYA programs, formally ending partnership

2 days ago talkbio0Tagged Collaboration termination, DNA Repair, drug development pipeline, Ideaya Biosciences, License Agreement, oncology partnership, Pol Theta, SmithKline Beecham, Synthetic Lethality, Werner helicase

GSK; IDEAYA Biosciences; synthetic lethality; collaboration termination; Werner helicase; Pol Theta; DNA damage repair; oncology partnership; license agreement; drug development pipeline

Servier Pays $210M Upfront for Ex-US Rights to Ideaya’s PKC Inhibitor Darovasertib

3 months ago talkbio0Tagged Clinical Trials, Darovasertib, Ideaya Biosciences, Inhibitor, milestone payments, oncology licensing deal, Protein Kinase C, Protein Kinase C Inhibitor, royalties, Servier, uveal melanoma

Servier; Ideaya Biosciences; darovasertib; protein kinase C inhibitor; PKC inhibitor; uveal melanoma; oncology licensing deal; clinical trials; milestone payments; royalties

Ideaya Secures $400M Deal for Biocytogen Bispecific ADC, Aiming to Enhance Drug Combinations

1 year ago talkbio0Tagged biobucks, Biocytogen, bispecific ADC, DNA damage repair molecules, Drug Combinations, Ideaya Biosciences

Ideaya Biosciences, Biocytogen, bispecific ADC, drug combinations, $400M deal, biobucks, DNA damage repair molecules